116 related articles for article (PubMed ID: 21741685)
1. Novel immunotherapy for metastatic bladder cancer using vaccine of human interleukin-2 surface-modified MB 49 cells.
Zhang X; Shi X; Li J; Hu Z; Guo F; Huang X; Zhang Z; Sun P; Jing Y; Gao J; Tan W
Urology; 2011 Sep; 78(3):722.e1-722.e6. PubMed ID: 21741685
[TBL] [Abstract][Full Text] [Related]
2. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer.
Zhang X; Shi X; Li J; Hu Z; Zhou D; Gao J; Tan W
J Urol; 2012 Mar; 187(3):1071-9. PubMed ID: 22266013
[TBL] [Abstract][Full Text] [Related]
3. Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer.
Shi X; Zhang X; Li J; Guo F; Hu Z; Jing Y; Bai L; Chen S; Wan P; Wang F; Gao J; Tan W
Urol Oncol; 2013 Aug; 31(6):883-93. PubMed ID: 21924648
[TBL] [Abstract][Full Text] [Related]
4. Development of a therapy against metastatic bladder cancer using an interleukin-2 surface-modified MB49 bladder cancer stem cells vaccine.
Zhu YT; Pang SY; Lei CY; Luo Y; Chu QJ; Tan WL
Stem Cell Res Ther; 2015 Nov; 6():224. PubMed ID: 26566931
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic potential of SA-sCD40L in the orthotopic model of superficial bladder cancer.
Zhang Z; Xu X; Zhang X; Chen X; Chen Q; Dong L; Hu Z; Li J; Gao J
Acta Oncol; 2011 Oct; 50(7):1111-8. PubMed ID: 21247263
[TBL] [Abstract][Full Text] [Related]
6. [Intravesical anchoring of streptavidin-tagged interleukin-4 fusion protein for immunotherapy of mouse superficial bladder cancer].
Zhang Z; Xu XL; Ma L; Li JL; Hu ZM; Gao JM
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):331-5. PubMed ID: 22883451
[TBL] [Abstract][Full Text] [Related]
7. [Interleukin-21 surface-modified MB49 cell vaccine for treatment of metastatic bladder in mice].
Peng J; Shi X; Chen D; Liang Z; Lan K; Gao J; Tan W
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Jun; 32(6):807-11. PubMed ID: 22699059
[TBL] [Abstract][Full Text] [Related]
8. [Immobilization of streptavidin-tagged bioactive hTNF-alpha on biotinylated mucosal surface of the bladder wall for treatment of superficial bladder cancer in mice].
Chen Z; Tan WL; Huang X; Liang ZK; Xu CX; Gao JM
Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):936-40. PubMed ID: 20501361
[TBL] [Abstract][Full Text] [Related]
9. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer.
Zhang P; Wang J; Wang D; Wang H; Shan F; Chen L; Hou Y; Wang E; Lu CL
Int Immunopharmacol; 2012 Nov; 14(3):252-60. PubMed ID: 22884511
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy against metastatic bladder cancer by combined administration of granulocyte macrophage-colony stimulating factor and interleukin-2 surface modified MB49 bladder cancer stem cells vaccine.
Wang CY; Hua R; Liu L; Zhan X; Chen S; Quan S; Chu QJ; Zhu YT
Cancer Med; 2017 Mar; 6(3):689-697. PubMed ID: 28205361
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell transfected with secondary lymphoid-tissue chemokine and/or interleukin-2 gene-enhanced cytotoxicity of T-lymphocyte in human bladder tumor cell S in vitro.
Li YG; Wang ZP; Tian JQ; Tian BQ; Rodrigues R; Shang PF; Zhang T
Cancer Invest; 2009 Nov; 27(9):909-17. PubMed ID: 19832038
[TBL] [Abstract][Full Text] [Related]
13. The granulocyte macrophage-colony stimulating factor surface modified MB49 bladder cancer stem cells vaccine against metastatic bladder cancer.
Zhu YT; Zhao Z; Fu XY; Luo Y; Lei CY; Chen W; Li F; Pang SY; Chen SS; Tan WL
Stem Cell Res; 2014 Jul; 13(1):111-22. PubMed ID: 24874290
[TBL] [Abstract][Full Text] [Related]
14. A novel immunotherapy for superficial bladder cancer by the immobilization of streptavidin-tagged bioactive IL-2 on the biotinylated mucosal surface of the bladder wall.
Huang X; Yu HS; Chen Z; Li JL; Hu ZM; Gao JM
Chin J Cancer; 2010 Jun; 29(6):611-6. PubMed ID: 20507734
[TBL] [Abstract][Full Text] [Related]
15. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant.
Sturmhoefel K; Lee K; Gray GS; Thomas J; Zollner R; O'Toole M; Swiniarski H; Dorner A; Wolf SF
Cancer Res; 1999 Oct; 59(19):4964-72. PubMed ID: 10519410
[TBL] [Abstract][Full Text] [Related]
16. Induction of antitumor immunity with combination of HER2/neu DNA vaccine and interleukin 2 gene-modified tumor vaccine.
Chen SA; Tsai MH; Wu FT; Hsiang A; Chen YL; Lei HY; Tzai TS; Leung HW; Jin YT; Hsieh CL; Hwang LH; Lai MD
Clin Cancer Res; 2000 Nov; 6(11):4381-8. PubMed ID: 11106257
[TBL] [Abstract][Full Text] [Related]
17. Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition.
Lindqvist C; Sandin LC; Fransson M; Loskog A
J Immunother; 2009 Oct; 32(8):785-92. PubMed ID: 19752755
[TBL] [Abstract][Full Text] [Related]
18. [Application of a tumor cell vaccine transfected with GM-CSF/IL-2 fusion gene for specific immunotherapy of hepatocellular carcinoma].
Guo C; Liu QG; Yang W; Yao YM
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Feb; 28(2):188-92. PubMed ID: 18250039
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity.
O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
J Urol; 2004 Mar; 171(3):1330-5. PubMed ID: 14767343
[TBL] [Abstract][Full Text] [Related]
20. Cytokine gene modification of bladder cancer cells for the establishment of bladder cancer vaccine.
Saito S; Tazaki H; Heston WD; Fair WR
Int J Urol; 1996 Jan; 3(1 Suppl):S35-9. PubMed ID: 24304018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
